Applied Products
Core technology is the foundation of a wide range of innovative applied products
SGI and its business units have developed key partnerships and agreements with multiple industry leaders. For more information about our business and how to partner with us, please contact our Corporate Development team at collaborations@syntheticgenomics.com.
Creating novel solutions and
transforming existing products
Applied products
Health
Flu Vaccines, Gene/Cell Therapy, Biologics, Organ Transplants, Antimicrobials
Nutrition
Dietary Supplements, Food Ingredients, Omega 3 Oils, Algal Protein
Bio-Industrial
Renewable Chemicals, Bio-based Intermediates, Plant Enhancement and Protection, Algal Biofuel
Current Partnered Programs
Non-GMO algal omega-3 DHA
Developing products containing Omega-3 Docosahexaenoic Acid (DHA) from a non-genetically modified algae strain.
Algal biofuel
SGI and ExxonMobil are focused on researching and developing naturally occurring and conventionally modified algae strains for use in developing algae-based biofuels.
Multivalent RNA-based vaccines
SGI, JCVI and GSK are collaborating to develop and evaluate multivalent RNA-based vaccines for protection against a highly diverse infectious disease pathogen.
Rapid precision flu vaccine
SGI employed synthetic genomics tools and technologies developed by our team to accelerate the production of the influenza vaccine seeds required for vaccine manufacturing.
Mammalian cell engineering
SGI and United Therapeutics have joined together to address the critical unmet organ need through xenotransplantation, the use of pigs as an essentially unlimited source of donor organs.
Researching novel human therapeutics
SGI is applying its proprietary synthetic biology technologies in collaboration with Merck, known as MSD outside the US and Canada, to develop novel therapies to treat human disease.